Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Construction of a Liver Metabolic Atlas in Biliary Atresia Based on Raman Spectroscopic Imaging

11 de novembro de 2026 atualizado por: Weibing Tang, Nanjing Children's Hospital

A Study on the Construction of a Liver Metabolic Atlas in Biliary Atresia Based on Raman Spectroscopic Imaging and Its Prognostic Evaluation Value

Biliary atresia (BA) is a severe infantile cholangiopathy characterized by progressive inflammation and fibrotic obliteration of the intra- and extrahepatic bile ducts. Although Kasai portoenterostomy can restore bile drainage, more than 50% of affected infants still progress to end-stage liver disease and require liver transplantation. BA is not merely a structural biliary obstruction but a complex liver disease involving cholestasis, oxidative stress, mitochondrial dysfunction, lipid peroxidation, bile acid metabolic disorders, and collagen deposition. Current clinical assessment relies mainly on serum liver function tests and semi-quantitative histological scoring, which cannot reveal the overall metabolic landscape or spatial heterogeneity of the liver. Raman imaging is a label-free, high-spatial-resolution molecular vibrational imaging technique that can simultaneously detect lipids, proteins, nucleic acids, glycogen, collagen, bilirubin, bile acids, and oxidative stress products. It has demonstrated metabolic phenotyping capability in tumor heterogeneity, organ development, and nonalcoholic fatty liver disease. However, the in situ spatial distribution of metabolites in BA liver-especially metabolic differences among portal, parenchymal, and centrilobular regions, the metabolic microenvironment around bile duct reaction foci, and metabolic boundaries of fibrous septa-remains unexplored by conventional metabolomics. Preliminary studies by our group have identified collagen deposition, oxidative stress, and bile acid metabolic abnormalities in BA liver. We hypothesize that BA liver undergoes coordinated metabolic reprogramming that forms characteristic Raman-capturable metabolic signatures, which may serve as novel tools for disease stratification and prognosis prediction. This study aims to construct a Raman-based liver metabolic atlas and evaluate its prognostic value.

Visão geral do estudo

Status

Ainda não está recrutando

Descrição detalhada

Biliary atresia (BA) is a severe infantile cholangiopathy characterized by progressive inflammation and fibrotic obliteration of the intrahepatic and extrahepatic bile ducts. Kasai portoenterostomy can temporarily restore bile drainage, but more than 50% of affected infants still progress to end-stage liver disease and require liver transplantation. BA is not merely a structural biliary obstruction; it is a complex liver disease involving cholestasis, oxidative stress, mitochondrial dysfunction, lipid peroxidation, bile acid metabolic disorders, and collagen deposition. Current clinical assessment relies mainly on conventional serum liver function indices (ALT, AST, GGT, TBIL, DBIL, and TBA) and semi-quantitative histopathological scoring. These approaches cannot reveal the overall metabolic landscape or the spatial heterogeneity of the liver, resulting in a lack of systematic understanding of metabolic reprogramming in BA.

Raman imaging is a label-free molecular vibrational spectroscopic imaging technique based on inelastic scattering. It can simultaneously detect chemical bond information from lipids, proteins, nucleic acids, glycogen, collagen, bilirubin, bile acids, and oxidative stress products without exogenous probes or labels, and it offers high spatial resolution and non-destructive detection. Raman imaging has demonstrated metabolic phenotyping capability in tumor metabolic heterogeneity, organ development, and nonalcoholic fatty liver disease. Previous studies suggest that BA patients have multiple metabolic abnormalities, including bile acid metabolic disorders. However, the in situ spatial distribution of metabolites in BA liver-especially metabolic differences among portal, parenchymal, and centrilobular regions, the metabolic microenvironment around bile duct reaction foci, and the metabolic boundaries of fibrous septa-cannot be obtained by conventional metabolomics, representing an important research gap. Raman imaging has the unique advantage of "spatial metabolomics," enabling metabolic information to be localized to specific pathological structures and providing a new dimension for understanding the relationship between intrahepatic metabolic heterogeneity and disease progression. Preliminary studies by our group have identified collagen deposition, oxidative stress, and bile acid metabolic abnormalities in BA liver. We hypothesize that BA liver undergoes coordinated metabolic reprogramming during pathological progression, forming characteristic Raman-capturable metabolic signatures that can comprehensively quantify multidimensional metabolic features and serve as novel tools for disease stratification and prognosis prediction.

Briefly, this single-center prospective observational study will enroll 60 infants with BA undergoing Kasai portoenterostomy and 20 age-matched controls (10 choledochal cysts and 10 intrahepatic cholestasis without BA). Intraoperative liver tissues will be collected and analyzed by confocal Raman imaging with near-infrared excitation and large-area multi-region scanning. HE and Masson staining and image registration will link spectral pixels to histological structures. A full-spectrum database will be established, and spectral unmixing will generate spatial metabolic heat maps, regional metabolic fingerprints, and metabolic gradients. Raman-derived parameters will be integrated with clinical and pathological data to develop a metabolic classification and a prognostic model for native liver survival using Cox and LASSO regression. Participants will be followed for at least 3 years. Primary outcomes are jaundice clearance and native liver survival after Kasai surgery; secondary outcomes include postoperative biochemical indices and liver stiffness. The study poses minimal risk, involves no new drugs or devices, and will be conducted with informed consent and ethical approval.

Tipo de estudo

Observacional

Inscrição (Estimado)

80

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

  • Nome: Zequan Ding
  • Número de telefone: +8613057659508
  • E-mail: dingzqcn@163.com

Locais de estudo

      • Nnajing, China
        • Nanjing Children's Hospital
        • Contato:

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

2 semanas a 6 meses (Filho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Método de amostragem

Amostra de Probabilidade

População do estudo

Patients with biliary atresia and undergoing Kasai surgery.

Descrição

Inclusion Criteria:

  • 1. Obtain the informed consent from the parents of the patients; 2. Children diagnosed with biliary atresia and undergoing Kasai surgery; 3. The control group consists of children with age-matched choledochal cysts and those with intrahepatic cholestasis excluding biliary atresia; 4. The medical records are complete.

Exclusion Criteria:

  • 1. Without obtaining the informed consent of the parents; 2. Children diagnosed with biliary atresia through cholangiography but not undergoing the Kasai surgery; 3. Children with incomplete medical records.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Modelos de observação: COHORT
  • Perspectivas de Tempo: PROSPECTIVE

Coortes e Intervenções

Grupo / Coorte
Intervenção / Tratamento
Biliary atresia

Biliary atresia patients who undergo Kasai surgery

All the intraoperative liver biopsy tissues of the participants will undergo Raman imaging to assess the metabolic status of the liver tissues.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Juandice clearance
Prazo: 3 months post Kasai augery

Serum direct bilirubin < 2mg/dL

3 months post Kasai augery

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Native liver survival
Prazo: 2 years post Kasai augery

Native liver survival without liver transplantation or death

2 years post Kasai augery

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

10 de novembro de 2026

Conclusão Primária (Estimado)

10 de março de 2027

Conclusão do estudo (Estimado)

30 de setembro de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

11 de novembro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

11 de novembro de 2026

Primeira postagem (Real)

17 de novembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

17 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

11 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

De-identified individual participant data (including demographic, clinical, and outcome variables) collected during the trial will be made available to qualified researchers.

Prazo de Compartilhamento de IPD

Data will become accessible:Starting Date: 6 months after study completion;End Date: Minimum 5 years after publication.

Critérios de acesso de compartilhamento IPD

Access to IPD requires submitting a formal research proposal (including hypothesis/analysis plan, ethical approval proof if applicable, and conflict of interest disclosure) to the investigator's email, along with a signed Data Use Agreement (DUA) prohibiting re-identification, commercial use, and redistribution.

Tipo de informação de suporte de compartilhamento de IPD

  • PROTOCOLO DE ESTUDO
  • SEIVA
  • CIF
  • ANALYTIC_CODE
  • CSR

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever